ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · IEX Real-Time Price · USD
18.41
+0.26 (1.43%)
At close: Jul 2, 2024, 4:00 PM
18.43
+0.02 (0.11%)
After-hours: Jul 2, 2024, 4:59 PM EDT
ArriVent BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
616.62M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAVBP News
- 27 days ago - ArriVent Announces a Multi-Target ADC Collaboration with Alphamab - GlobeNewsWire
- 6 weeks ago - ArriVent Appoints John Hohneker, M.D., to its Board of Directors - GlobeNewsWire
- 7 weeks ago - ArriVent BioPharma Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - ArriVent Appoints Kristine Peterson to its Board of Directors - GlobeNewsWire
- 3 months ago - InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib - Business Wire
- 3 months ago - ArriVent BioPharma Reports Full Year 2023 Financial Results - GlobeNewsWire
- 5 months ago - ArriVent Announces Pricing of Upsized Initial Public Offering - GLOBE NEWSWIRE
- 6 months ago - Cancer biotech ArriVent Biopharma files for a $100 million IPO - Renaissance Capital